A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol

[1]  G. Gigli,et al.  Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal Cannabis sativa Variety: Δ9-Tetrahydrocannabutol, the Butyl Homologue of Δ9-Tetrahydrocannabinol. , 2019, Journal of natural products.

[2]  L. Degenhardt,et al.  Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. , 2019, The lancet. Psychiatry.

[3]  G. Gigli,et al.  Analysis of impurities of cannabidiol from hemp. Isolation, characterization and synthesis of cannabidibutol, the novel cannabidiol butyl analog. , 2019, Journal of pharmaceutical and biomedical analysis.

[4]  A. Giorgi,et al.  Phytochemical and Ecological Analysis of Two Varieties of Hemp (Cannabis sativa L.) Grown in a Mountain Environment of Italian Alps , 2019, Front. Plant Sci..

[5]  G. Gigli,et al.  Chemical and spectroscopic characterization data of ‘cannabidibutol’, a novel cannabidiol butyl analog , 2019, Data in brief.

[6]  F. Forni,et al.  Cannabinoid Profiling of Hemp Seed Oil by Liquid Chromatography Coupled to High-Resolution Mass Spectrometry , 2019, Front. Plant Sci..

[7]  Steven C. R. Williams,et al.  Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder , 2019, Neuropsychopharmacology.

[8]  G. Leo,et al.  Untargeted rat brain metabolomics after oral administration of a single high dose of cannabidiol , 2018, Journal of pharmaceutical and biomedical analysis.

[9]  S. Benvenuti,et al.  New Methods for the Comprehensive Analysis of Bioactive Compounds in Cannabis sativa L. (hemp) , 2018, Molecules.

[10]  A. Cho,et al.  Exploring the Ligand Efficacy of Cannabinoid Receptor 1 (CB1) using Molecular Dynamics Simulations , 2018, Scientific Reports.

[11]  Giuseppe Cannazza,et al.  A Metabolomic Approach Applied to a Liquid Chromatography Coupled to High-Resolution Tandem Mass Spectrometry Method (HPLC-ESI-HRMS/MS): Towards the Comprehensive Evaluation of the Chemical Composition of Cannabis Medicinal Extracts. , 2018, Phytochemical analysis : PCA.

[12]  Maria Paola Costi,et al.  Aryl thiosemicarbazones for the treatment of trypanosomatidic infections. , 2018, European journal of medicinal chemistry.

[13]  M. Zoli,et al.  Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD. , 2018, Journal of pharmaceutical and biomedical analysis.

[14]  F. Forni,et al.  Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA) , 2018, Journal of pharmaceutical and biomedical analysis.

[15]  Giuseppe Cannazza,et al.  Pharmaceutical and biomedical analysis of cannabinoids: A critical review , 2018, Journal of pharmaceutical and biomedical analysis.

[16]  V. Aggarwal,et al.  Asymmetric Synthesis of Tertiary Alcohols and Thiols via Nonstabilized Tertiary α‐Oxy‐ and α‐Thio‐Substituted Organolithium Species , 2017, Angewandte Chemie.

[17]  Shan Jiang,et al.  Crystal structures of agonist-bound human cannabinoid receptor CB1 , 2017, Nature.

[18]  P. Piazza,et al.  Cannabinoid‐Induced Tetrad in Mice , 2017, Current protocols in neuroscience.

[19]  Benjamin J. Whalley,et al.  A cannabigerol-rich Cannabis sativa extract, devoid of [INCREMENT]9-tetrahydrocannabinol, elicits hyperphagia in rats , 2017, Behavioural pharmacology.

[20]  Ethan B. Russo.  Cannabis and epilepsy: An ancient treatment returns to the fore , 2017, Epilepsy & Behavior.

[21]  Ethan B. Russo.  Cannabidiol Claims and Misconceptions. , 2017, Trends in pharmacological sciences.

[22]  L. Lo Presti,et al.  Probing an Allosteric Pocket of CDK2 with Small Molecules , 2017, ChemMedChem.

[23]  G. Appendino,et al.  Phytocannabinoids: a unified critical inventory. , 2016, Natural product reports.

[24]  Jie Yin,et al.  High-resolution crystal structure of the human CB1 cannabinoid receptor , 2016, Nature.

[25]  J. Rimoldi,et al.  The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation , 2016, Perspectives in medicinal chemistry.

[26]  E. Meijer,et al.  The inheritance of chemical phenotype in Cannabis sativa L. (V): regulation of the propyl-/pentyl cannabinoid ratio, completion of a genetic model , 2016, Euphytica.

[27]  G. Novack.  Cannabinoids for treatment of glaucoma , 2016, Current opinion in ophthalmology.

[28]  M. Zoli,et al.  7-Chloro-5-(furan-3-yl)-3-methyl-4H-benzo[e][1,2,4]thiadiazine 1,1-Dioxide as Positive Allosteric Modulator of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor. The End of the Unsaturated-Inactive Paradigm? , 2016, ACS chemical neuroscience.

[29]  H. de Wit,et al.  A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial , 2015, PloS one.

[30]  I. Salloum,et al.  Polysomnographic sleep disturbances in nicotine, caffeine, alcohol, cocaine, opioid, and cannabis use: A focused review. , 2015, The American journal on addictions.

[31]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[32]  Blair H. Smith,et al.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis , 2015, The Lancet Neurology.

[33]  R. Papke,et al.  The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors , 2014, Psychopharmacology.

[34]  R. Niesink,et al.  Does Cannabidiol Protect Against Adverse Psychological Effects of THC? , 2013, Front. Psychiatry.

[35]  Benjamin J. Whalley,et al.  Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism , 2013, British journal of pharmacology.

[36]  G. Bedi,et al.  Subjective, cognitive and cardiovascular dose‐effect profile of nabilone and dronabinol in marijuana smokers , 2013, Addiction biology.

[37]  J. Hobart,et al.  MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[38]  L. Brasili,et al.  5-Arylbenzothiadiazine Type Compounds as Positive Allosteric Modulators of AMPA/Kainate Receptors. , 2012, ACS medicinal chemistry letters.

[39]  Anna L. Bowman,et al.  Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. , 2010, Journal of medicinal chemistry.

[40]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[41]  P. Robson,et al.  Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex®, a Cannabis‐Based Medicine , 2007, Chemistry & biodiversity.

[42]  M. Vallejos,et al.  Full exploitation of Cannabis sativa as reinforcement/filler of thermoplastic composite materials , 2007 .

[43]  쿠퍼 로버트제이.  Cannabinoid active pharmaceutical ingredient for improved dosage forms , 2006 .

[44]  A. Lichtman,et al.  Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[45]  S. Nikas,et al.  The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model , 2004, The AAPS Journal.

[46]  Y. Choi,et al.  NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. , 2004, Phytochemical analysis : PCA.

[47]  E. Carlini.  The good and the bad effects of (−) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humans , 2004 .

[48]  S. Nikas,et al.  Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. , 2003, Journal of medicinal chemistry.

[49]  John R. Miller,et al.  Structure–activity relationships for 1′,1′-dimethylalkyl-Δ 8 -tetrahydrocannabinols , 2003 .

[50]  S. Nikas,et al.  Novel 1′,1′-chain substituted Δ8-tetrahydrocannabinols , 2002 .

[51]  S. Nikas,et al.  Synthesis of side chain specifically deuterated (-)-Δ9-tetrahydrocannabinols , 2002 .

[52]  H. de Wit,et al.  Comparison of the subjective effects of Δ9-tetrahydrocannabinol and marijuana in humans , 2002, Psychopharmacology.

[53]  R. Razdan,et al.  Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. , 1999, The Journal of pharmacology and experimental therapeutics.

[54]  P. Casellas,et al.  Characterization of two cloned human CB1 cannabinoid receptor isoforms. , 1996, The Journal of pharmacology and experimental therapeutics.

[55]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[56]  L. Robertson,et al.  Biotransformation of cannabinoids by Syncephalastrum racemosum , 1975 .

[57]  R. Mechoulam,et al.  Syntheses of .DELTA.1-tetrahydrocannabinol and related cannabinoids , 1972 .

[58]  S. Loewe,et al.  Tetrahydrocannabinol Homologs with Marihuana Activity. IX1 , 1941 .

[59]  W. Westerhuis.  Hemp for textiles : plant size matters , 2016 .

[60]  M. Piraux,et al.  The biogenesis of cannabinoids in Cannabis sativa , 1982 .

[61]  O. Schultz,et al.  Zur Frage der Biosynthese der Cannabinole , 1960 .